News >

Studies Seek to Expand on PARP Inhibitor Success in Ovarian Cancer

Gina Columbus @ginacolumbusonc
Published: Tuesday, Jan 29, 2019

Susana M. Campos, MD
Susana M. Campos, MD
With 3 PARP inhibitors available for patients with recurrent ovarian cancer and in the maintenance setting, Susana Campos, MD, MPH, said that ongoing clinical trials will answer questions about where the future management of the disease is headed.

on Ovarian Cancer, Campos highlighted the success with PARP inhibitors in the relapsed and maintenance ovarian cancer settings.

OncLive: Could you highlight the key takeaways from your presentation on PARP inhibitors?

Campos: We talked about PARP inhibitors and how they have infiltrated the world of ovarian cancer, and in many ways how they have changed the course of ovarian cancer. I spoke a bit about what some of the PARP inhibitors are in the recurrent setting as single agents—where it all started.

We also spoke about interesting data about the SOLO-1 trial, which was a highlight of the 2018 ESMO Congress. Then, we talked about if PARP inhibitors work as single agents, what if we were to combine them with other agents, such as antiangiogenic agents? In terms of immunotherapy, my colleague [Panagiotis A. Konstantinopoulos, MD] also spoke on PARP inhibitors and immunotherapy. Therefore, in my lecture, we talked about where [PARP inhibition] started, where it is today, and where we think we're going tomorrow [with them].

The SOLO-1 trial had practice-changing findings. Could you highlight that study and the data?

The SOLO-1 trial was specifically in BRCA-mutation carriers, so patients in the upfront setting, after they finished chemotherapy and if they were in complete remission, were subsequently randomized to an intervention, which in this case was olaparib or placebo, and they were followed.

They were on treatment for about 2 years, and in a landmark analysis of about 3 years, it was striking because of the patients who were randomized to olaparib, at least 60% were progression free at that time as opposed to about 24% [who had placebo]. This is statistically significant. Where this pans out in the future, [the question is], does it improve OS? It is too early to tell. These are not mature results, but at least at first blush, these are incredibly exciting data. Everyone in the room understands and gets a chill when they actually see these data.

What are the differences between the 3 available PARP inhibitors?

We know, in essence, that they are pretty similar. There are olaparib, niraparib (Zejula), and rucaparib. There are going to be more at the end of the day. We know that they have some common side effects; for example, there is anemia, thrombocytopenia, and leukopenia. We know that there are gastrointestinal toxicities, but some of them have some unique toxicities.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication